cgtlive.com

Backlink analytics and domain authority

Backlinks

All Dofollow Nofollow UGC DR ▾ Ref. domains ▾ + Add filter

50 backlinks All New Lost

Referring page	DR	Ref. domains	Linked domains	Anchor and target URL
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=20&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_205553719 med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=20&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_205553719 med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel med.stanford.edu	82	2,806	1,516	ImmunoLogic, Episode 7: https://www.cgtlive.com/view/immunologic-episode-7-il-9-car-t-therapy-kalbasi DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
news.html https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194 med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
news.html https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194 med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
Ceribell’s Status Epilepticus Software Receives FDA Clearance With CMS NTAP C... https://www.neurologylive.com/view/ceribell-status-epilepticus-software-receives-fda-clearance-with-cms-ntap-coverage-included neurologylive.com	74	176	25	CGT Live https://www.cgtlive.com/ DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_20555371 med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_20555371 med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
FDA Lifts Clinical Hold on IkT-148009 in Multiple System Atrophy \| NeurologyL... https://www.neurologylive.com/view/fda-lifts-clinical-hold-on-ikt-148009-multiple-system-atrophy neurologylive.com	74	176	25	CGT Live https://www.cgtlive.com/ DOFOLLOW
news.html https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
news.html https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5 med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5 med.stanford.edu	82	2,806	1,516	ImmunoLogic, Episode 7: https://www.cgtlive.com/view/immunologic-episode-7-il-9-car-t-therapy-kalbasi DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5 med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1 med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1 med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
EHR-Integrated Tool Shows Promise in Reducing Headache Referrals, Referral Ra... https://www.neurologylive.com/view/ehr-integrated-tool-promise-reducing-headache-referrals-referral-rates-institutional-economic-burden neurologylive.com	74	176	25	CGT Live https://www.cgtlive.com/ DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW
PRO-MSACTIVE Data Highlights Efficacy, Safety, and Patient-Reported Outcomes ... https://www.neurologylive.com/view/pro-msactive-data-highlights-efficacy-safety-patient-reported-outcomes-ocrelizumab-relapsing-ms neurologylive.com	74	176	25	CGT Live https://www.cgtlive.com/ DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T https://www.cgtlive.com/view/stanford-low-risk-secondary-blood-cancers-after-car-t DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Tr1X Doses First Patient in Trial Evaluating Allogeneic Treg Therapy TRX103 for GvHD Prevention https://www.cgtlive.com/view/tr1x-doses-first-patient-trial-evaluating-allogeneic-treg-therapy-trx103-gvhd-prevention DOFOLLOW

▾

Frequently Asked Questions

How many backlinks does cgtlive.com have?

The backlinks page for cgtlive.com shows all individual inbound links discovered in our crawl of the web. Each backlink represents a hyperlink on another website that points to a page on cgtlive.com. Use the filters to narrow results by dofollow/nofollow status, domain rating, or anchor text.

What is a backlink?

A backlink is a hyperlink on one website that points to a page on a different website. Backlinks are one of the most important ranking factors in search engine algorithms because they act as votes of confidence from other sites. The more high-quality backlinks a domain has, the more authority search engines assign to it.

Are the backlinks to cgtlive.com dofollow or nofollow?

Backlinks to cgtlive.com include both dofollow and nofollow links. Dofollow links pass link equity (ranking power) to the target site, while nofollow links include a rel="nofollow" attribute that tells search engines not to pass authority. Both types contribute to a natural backlink profile, but dofollow links carry more SEO weight. You can filter by link type using the rel filter above the table.

How often is backlink data updated?

Backlink data is updated monthly when our web crawler completes a new cycle. Our pipeline processes billions of web pages to discover new backlinks, track lost links, and update domain authority scores. The freshness of data depends on when our crawler last visited the referring pages.